All patients according to previous allo-HSCT. Event-free survival (A), overall survival (B) with estimates for 24 months after CAR T-cell infusion, relapse-free survival (C), and duration of B-cell aplasia (D) with estimates for 24 months after response. w/, with’ w/o, without.